Naproxen/esomeprazole magnesium in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

International Journal of Clinical Rheumatology

Volumn 7, Issue 1, 2012, Pages 21-31

  Dore, Robin K ^a   Locks, Megan ^a  

^a Robin K Dore MD Inc   (United States)

Author keywords

ankylosing spondylitis; naproxen esomeprazole; NSAID gastropathy; NSAIDs; osteoarthritis; rheumatoid arthritis

Indexed keywords

CELECOXIB; ESOMEPRAZOLE; ESOMEPRAZOLE PLUS NAPROXEN; ETORICOXIB; FAMOTIDINE PLUS IBUPROFEN; IBUPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLEEDING; CONSTIPATION; CONTUSION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENITIS; DYSPEPSIA; EROSIVE GASTRITIS; GASTRITIS; HEADACHE; HEART INFARCTION; HEARTBURN; HEMATEMESIS; HUMAN; IRON DEFICIENCY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OSTEOARTHRITIS; PEPTIC ULCER; PHARMACODYNAMICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK REDUCTION; SELF REPORT; STOMACH ULCER; STROKE; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84856668717     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.11.67     Document Type: Article

References (15)

1. Hochberg MC, Altman RD, Brandt KD et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arth. Rheum. 38, 1535-1540 (1995).
2. Hochberg MC, Altman RD, Brandt KD et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the hip. Arth. Rheum. 38, 1541-1546 (1995).
3. Altman RD, Hochberg RD, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arth. Rheum. 43, 1905-1915 (2000).
4. Silverstein FE, Graham DY, Senior JR et al. Misoprostol reduces serious gastrointestinal complications in patients with RA receiving NSAIDs: a randomized, double blind, placebo-controlled trial. Ann. Int. Med. 123, 241-249 (1995).
5. Raskin JB, White RH, Jackson JE et al. Misoprostol dosage in the prevention of NSAID-induced gastric and duodenal ulcers: a comparison of 3 regimens. Ann. Int. Med. 123, 344-350 (1995).
6. Zochling J, Bohl-Bühler MH, Baraliakos X, Braun J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis -a population-based survey. Clin. Rheum. 25(6), 794-800 (2006). (Pubitemid 44473141)
7. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of NSAIDs: results of a double-blind, randominzed multi-center, active and placebo-controlled study of misoprostol versus lansoprasole. Arch. Intern. Med. 162, 169-175 (2002). (Pubitemid 34098186)
8. Chey WD, Lukasik N, Huang B. Lansoprazole effectively reduces the risk of gastrointestinal symptom occurrence in ulcer-free patients who continue chronic NSAID use. Am. J. Gastroenterol. 98, 5296 (2003).
9. Abraham NS, El-Serag HB, Johnson ML et al. National adherence to evidence-based guidelines for the prescription of NSAIDs. Gastroenterology 129, 1171-1178 (2005). (Pubitemid 41446857)
10. Goldstein JL, Howard KB, Walton SM et al. Impact of adherence to concomitant therapy on NSAID related gastroduodenal ulcer complications. Clin. Gastroenterol. Hepatol. 4, 1337-1345 (2006).
11. Miner J, Plachetka J, Orlemans J, Fort G, Sostek M. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg; a randomized, open-label, Phase I study in healthy volunteers. Aliment. Pharmacol. Ther. 32, 414-424 (2010).
12. Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr. Gastroenterol. Rep. 12(6), 437-447 (2010).
13. Goldstein JL, Hochberg MC, Fort JG, Zhang Y, Sostek M. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Ailment. Pharmacol. Ther. 32, 401-413 (2010).
14. Sostek MB, Fort JG, Estborn L, Vikman K. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: Phase 3 study in patients at risk for NSAID-associated gastric ulcers. Curr. Med. Res. Opin. 27(4), 847-854 (2011).
15. Hochberg MC, Cryer BL, Fort JG, Hwang C, Svensson O, Sostek MB. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable efficacy and tolerability to celecoxib in patients with osteoarthritis (OA) of the knee: results from two randomized, controlled trials. Curr. Med. Res. Opin. 27(6), 1243-1253 (2011).